• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Levodopa for Parkinson’s disease more effective than newer generation therapies

byDevin MillerandXiaozhou Liu
June 11, 2014
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Levodopa provided a small but consistent benefit for treatment of Parkinson’s disease as compared to levodopa-sparing regimens including dopamine agonists and monoamine oxidase B inhibitors (MAOBIs). 

2. Among levodopa sparing regimens, MAOBIs were at least as effective as dopamine agonists. 

Evidence Rating Level: 2 (Good)            

Study Rundown: The optimal treatment in the initial stages of Parkinson’s disease is currently uncertain. While levodopa appears to control motor symptoms better than either monoamine oxidase B inhibitors (MAOBIs) or dopamine agonists, it also carries the highest risk for dyskinesias. MAOBIs and dopamine agonists; however, have a greater risk of causing non-motor side effects such as nausea and sleep disturbance. The authors of this study undertook the largest trial to date in order to identify the optimal treatment for Parkinson’s disease. The study found that there was a very small but persistent benefit in patient-rated mobility scores when treatment had been initiated with levodopa. The investigators also observed that MAOBIs was at least as effective as dopamine agonists. This study was strengthened by the large sample size. The focus on quality of life measures rather than control of motor symptoms provided a more holistic view of patient experience that has not been performed in prior research. This study, however, was limited by the fact that neither the patients nor investigators were blinded to the treatment conditions, introducing potential bias in the reports made by patients and observations made by investigators.

Click to read the study, published today in The Lancet

Relevant Reading: National Institute for Health and Clinical Excellence. Review of clinical guideline (CG 35)—Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care

In-Depth [randomized, open-label trial]: This study included 1620 patients diagnosed with Parkinson’s disease who were randomly assigned to receive levodopa, MAOBI, or dopamine agonists. Outcomes for the study included patient rated functional status according to the 39-item Parkinson’s Disease Questionnaire (PDQ-39), quality-adjusted life-years calculated from the EuroQol EQ-5D, as well as cognition, dyskinesia, hospital or institutional admissions, and mortality.

RELATED REPORTS

Adjuvant treatment with catechol-O-methyltransferase inhibitors inferior to monoamine oxidase type B inhibitors or dopamine agonists in patients with Parkinson disease uncontrolled by levodopa therapy

Physical activity is associated with a reduction in all-cause mortality in patients with newly diagnosed Parkinson Disease

Influenza is associated with an increased odds of Parkinson Disease diagnosis after 10 years

The authors found that PDQ-39 mobility scores were 1.8 (95% confidence interval, CI, 0.5 – 3.0, p = 0.005) points higher in patients who received levodopa than those who received levodopa-sparing treatment. EQ-5D utility scores were also better in patients receiving levodopa with scores being 0.03 (95% CI 0.01 – 0.05; p = 0.0002) points higher than those receiving levodopa sparing treatment. Rates of dementia, institutional admission, and mortality were not significantly different between the two groups. Patients in the levodopa group were more likely to develop dyskinesias compared to the levodopa-sparing group (hazard ratio [HR] 1.52, 95% CI 1.16-2.00, p = 0.003).

More from this author: Schizophrenia linked with higher rates of violence, suicide, and early mortality;Overall improvement in management of high blood pressure between 1994 and 2011;Link between early life antibiotic use, asthma exacerbations, and impaired viral immunity;Structural and neurobiological foundations of suicide, a review;Buccal administration of dextrose gel effective in treatment of neonatal hypoglycemia 

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: dyskinesialevodopaParkinson’s
Previous Post

Hydrolyzed formula in susceptible infants does not reduce Diabetes-linked autoantibodies

Next Post

Combination CPAP, weight loss for obstructive sleep apnea offer no added benefit

RelatedReports

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Chronic Disease

Adjuvant treatment with catechol-O-methyltransferase inhibitors inferior to monoamine oxidase type B inhibitors or dopamine agonists in patients with Parkinson disease uncontrolled by levodopa therapy

December 29, 2021
Adolescents’ muscle strength associated with lower cardiometabolic risk
Chronic Disease

Physical activity is associated with a reduction in all-cause mortality in patients with newly diagnosed Parkinson Disease

November 5, 2021
Influenza vaccine not associated with increased risk of epilepsy in children
Infectious Disease

Influenza is associated with an increased odds of Parkinson Disease diagnosis after 10 years

October 26, 2021
The LEAP trial: levodopa not associated with a disease-modifying effect in Parkinson’s disease
Chronic Disease

The LEAP trial: levodopa not associated with a disease-modifying effect in Parkinson’s disease

January 25, 2019
Next Post
ADHD stimulant treatment associated with changes in BMI trajectory

Combination CPAP, weight loss for obstructive sleep apnea offer no added benefit

Brodalumab effective in treating active psoriatic arthritis

Brodalumab effective in treating active psoriatic arthritis

Teledermatology may be reliable in triaging inpatient dermatology consultations

Primary melanoma regression may not be associated with reduced metastasis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.